Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.
Authors
- Neil M. Iyengar (ORCID: https://orcid.org/0000-0002-9773-5235)
- Erika Hamilton (ORCID: https://orcid.org/0000-0002-1911-0336)
- X. Cynthia
- Komal L. Jhaveri (ORCID: https://orcid.org/0000-0003-0472-1254)
- Sarah Donahue
- Heather Moore (ORCID: https://orcid.org/0000-0002-0619-3267)
- Joyce O’Shaughnessy (ORCID: https://orcid.org/0000-0001-6764-2807)
- Karen L. Tedesco
- Monali Vasekar (ORCID: https://orcid.org/0000-0003-2369-8133)
- Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
Institutions
- Pennsylvania State University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- University of California, San Francisco (US)
- Washington University in St. Louis (US)
- Cornell University (US)
- Texas Oncology (US)
- Baylor University Medical Center (US)
- Sarah Cannon (US)
- City of Hope (US)
- New York Oncology Hematology (US)
- Tennessee Oncology (US)
- Duke University Health System (US)
- The US Oncology Network (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- npj Breast Cancer
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1038/s41523-025-00864-2
- Citations
- 1
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81